NeOnc Technologies Holdings (NTHI) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
NTHI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
NeOnc Technologies Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.41 |
| 52 Week High | US$12.99 |
| 52 Week Low | US$2.96 |
| Beta | 0 |
| 1 Month Change | -38.34% |
| 3 Month Change | -35.29% |
| 1 Year Change | -71.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTHI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.8% | -0.07% | -1.1% |
| 1Y | -71.8% | 45.4% | 11.7% |
Return vs Industry: NTHI underperformed the US Pharmaceuticals industry which returned 45.4% over the past year.
Return vs Market: NTHI underperformed the US Market which returned 11.7% over the past year.
Price Volatility
| NTHI volatility | |
|---|---|
| NTHI Average Weekly Movement | 19.1% |
| Pharmaceuticals Industry Average Movement | 8.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NTHI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NTHI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 5 | Amir Heshmatpour | www.neonc.com |
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
NeOnc Technologies Holdings, Inc. Fundamentals Summary
| NTHI fundamental statistics | |
|---|---|
| Market cap | US$74.32m |
| Earnings (TTM) | -US$47.20m |
| Revenue (TTM) | US$39.99k |
Is NTHI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTHI income statement (TTM) | |
|---|---|
| Revenue | US$39.99k |
| Cost of Revenue | US$0 |
| Gross Profit | US$39.99k |
| Other Expenses | US$47.24m |
| Earnings | -US$47.20m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -118,029.51% |
| Debt/Equity Ratio | 0% |
How did NTHI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/17 22:50 |
| End of Day Share Price | 2026/09/17 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeOnc Technologies Holdings, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Thomas Shrader | BTIG |
| Jason McCarthy | Maxim Group |